Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Avadel Pharmaceuticals (AVDL) over the last 16 years, with Dec 2024 value amounting to $16.0 million.

  • Avadel Pharmaceuticals' Cash from Financing Activities was N/A to $6.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $14.5 million, marking a year-over-year change of. This contributed to the annual value of $16.0 million for FY2024, which is 88.20% down from last year.
  • According to the latest figures from FY2024, Avadel Pharmaceuticals' Cash from Financing Activities is $16.0 million, which was down 88.20% from $135.3 million recorded in FY2023.
  • Avadel Pharmaceuticals' 5-year Cash from Financing Activities high stood at $179.7 million for FY2020, and its period low was $263,000 during FY2021.
  • Over the past 3 years, Avadel Pharmaceuticals' median Cash from Financing Activities value was $16.0 million (recorded in 2024), while the average stood at $55.3 million.
  • As far as peak fluctuations go, Avadel Pharmaceuticals' Cash from Financing Activities skyrocketed by 665,592.59% in 2020, and later crashed by 99.85% in 2021.
  • Over the past 5 years, Avadel Pharmaceuticals' Cash from Financing Activities (MRY) stood at $179.7 million in 2020, then plummeted by 99.85% to $263,000 in 2021, then soared by 5,429.66% to $14.5 million in 2022, then soared by 830.59% to $135.3 million in 2023, then tumbled by 88.20% to $16.0 million in 2024.
  • Its Cash from Financing Activities stands at $16.0 million for FY2024, versus $135.3 million for FY2023 and $14.5 million for FY2022.